148 related articles for article (PubMed ID: 38633254)
1. Case report: EBV-related eye orbits and sinuses lymphohistiocytic infiltration responsive to rituximab in a patient with X lymphoproliferative syndrome type 1.
Giardino G; Lanni V; Mascolo M; Russo D; Cirillo E; Romano R; Cillo F; Grilli L; Prencipe MR; Iuliano A; Uccello G; De Fusco C; Menna G; Scalia G; Portella G; Pignata C
Front Immunol; 2024; 15():1370991. PubMed ID: 38633254
[TBL] [Abstract][Full Text] [Related]
2. Single-Cell Transcriptomic Analysis of Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis.
Suzuki T; Sato Y; Okuno Y; Torii Y; Fukuda Y; Haruta K; Yamaguchi M; Kawamura Y; Hama A; Narita A; Muramatsu H; Yoshikawa T; Takahashi Y; Kimura H; Ito Y; Kawada JI
J Clin Immunol; 2024 Apr; 44(4):103. PubMed ID: 38642164
[TBL] [Abstract][Full Text] [Related]
3. X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease.
Booth C; Gilmour KC; Veys P; Gennery AR; Slatter MA; Chapel H; Heath PT; Steward CG; Smith O; O'Meara A; Kerrigan H; Mahlaoui N; Cavazzana-Calvo M; Fischer A; Moshous D; Blanche S; Pachlopnik Schmid J; Latour S; de Saint-Basile G; Albert M; Notheis G; Rieber N; Strahm B; Ritterbusch H; Lankester A; Hartwig NG; Meyts I; Plebani A; Soresina A; Finocchi A; Pignata C; Cirillo E; Bonanomi S; Peters C; Kalwak K; Pasic S; Sedlacek P; Jazbec J; Kanegane H; Nichols KE; Hanson IC; Kapoor N; Haddad E; Cowan M; Choo S; Smart J; Arkwright PD; Gaspar HB
Blood; 2011 Jan; 117(1):53-62. PubMed ID: 20926771
[TBL] [Abstract][Full Text] [Related]
4. Case Report: Meningoencephalitis With Thrombotic Occlusive Vasculopathy in a Young EBV-Naïve Boy Is Associated With a Novel
Steininger J; Rossmanith R; Geier CB; Leiss-Piller A; Thonhauser L; Weiss S; Hainfellner JA; Freilinger M; Schmidt WM; Eibl MM; Wolf HM
Front Immunol; 2021; 12():747738. PubMed ID: 34987501
[TBL] [Abstract][Full Text] [Related]
5. Diagnosing XLP1 in patients with hemophagocytic lymphohistiocytosis.
Meazza R; Tuberosa C; Cetica V; Falco M; Parolini S; Grieve S; Griffiths GM; Sieni E; Marcenaro S; Micalizzi C; Montin D; Fagioli F; Moretta A; Mingari MC; Moretta L; Notarangelo LD; Bottino C; Aricò M; Pende D
J Allergy Clin Immunol; 2014 Dec; 134(6):1381-1387.e7. PubMed ID: 24985396
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus-related hemophagocytic lymphohistiocytosis complicated with coronary artery dilation and acute renal injury in a boy with a novel X-linked inhibitor of apoptosis protein (XIAP) variant: a case report.
Chen RY; Li XZ; Lin Q; Zhu Y; Shen YY; Xu QY; Zhu XM; Bai ZJ; Li Y
BMC Pediatr; 2020 Oct; 20(1):456. PubMed ID: 33008347
[TBL] [Abstract][Full Text] [Related]
7. X-linked Lymphoproliferative Disease (XLP1) Presenting as Non-Epstein Barr Virus (EBV) - Related Hemophagocytic Lymphohistiocytosis (HLH).
Loganathan A; Munirathnam D; Sundaram B
Indian Pediatr; 2020 Nov; 57(11):1077-1078. PubMed ID: 33231181
[No Abstract] [Full Text] [Related]
8. X-Linked Lymphoproliferative Disease Type 1: A Clinical and Molecular Perspective.
Panchal N; Booth C; Cannons JL; Schwartzberg PL
Front Immunol; 2018; 9():666. PubMed ID: 29670631
[TBL] [Abstract][Full Text] [Related]
9. The ambiguous boundary between EBV-related hemophagocytic lymphohistiocytosis and systemic EBV-driven T cell lymphoproliferative disorder.
Smith MC; Cohen DN; Greig B; Yenamandra A; Vnencak-Jones C; Thompson MA; Kim AS
Int J Clin Exp Pathol; 2014; 7(9):5738-49. PubMed ID: 25337215
[TBL] [Abstract][Full Text] [Related]
10. Systemic Epstein-Barr Virus-Positive T/NK Lymphoproliferative Diseases With
Ishimura M; Eguchi K; Shiraishi A; Sonoda M; Azuma Y; Yamamoto H; Imadome KI; Ohga S
Front Pediatr; 2019; 7():183. PubMed ID: 31231620
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens.
Chellapandian D; Das R; Zelley K; Wiener SJ; Zhao H; Teachey DT; Nichols KE;
Br J Haematol; 2013 Aug; 162(3):376-82. PubMed ID: 23692048
[TBL] [Abstract][Full Text] [Related]
12. Exon skipping caused by a complex structural variation in SH2D1A resulted in X-linked lymphoproliferative syndrome type 1.
Wu L; Yang F; Wang J; Yang F; Liang M; Yang H
Mol Genet Genomic Med; 2022 Mar; 10(3):e1873. PubMed ID: 35092357
[TBL] [Abstract][Full Text] [Related]
13. Fatal X-linked lymphoproliferative disease type 1-associated limbic encephalitis with positive anti-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antibody.
Ochiai S; Hayakawa I; Ohashi E; Hamano S; Miyata Y; Sakuma H; Hogetsu K; Gocho Y; Ogura M; Uchiyama T; Abe Y
Brain Dev; 2022 Oct; 44(9):630-634. PubMed ID: 35778314
[TBL] [Abstract][Full Text] [Related]
14. Systemic Epstein-Barr virus positive T-cell lymphoproliferative disease of childhood with hemophagocytic syndrome.
Chen G; Chen L; Qin X; Huang Z; Xie X; Li G; Xu B
Int J Clin Exp Pathol; 2014; 7(10):7110-3. PubMed ID: 25400806
[TBL] [Abstract][Full Text] [Related]
15. X-Linked Lymphoproliferative Syndrome: A Spectrum of Clinical and Immunological Profile and Novel Pathogenic Variants from Chandigarh, India.
Jindal AK; Mondal S; Sil A; Rawat A; Chawla S; Tyagi R; Sudhakar M; Banday AZ; Suri D; Vignesh P; Dhaliwal M; Sharma S; Rikhi R; Saka R; Sharma R; Chatterjee D; Sreedharanunni S; Uppuluri R; Raj R; Singh S
Int Arch Allergy Immunol; 2024; 185(4):370-381. PubMed ID: 38194943
[TBL] [Abstract][Full Text] [Related]
16. The emergence of CD20-/CD19- tumor cells after rituximab therapy for Epstein-Barr virus-associated post-transplant lymphoproliferative disorder complicated with hemophagocytic lymphohistiocytosis.
Yamamoto N; Nishimura N; Takeuchi M; Ito T; Yokozaki H; Hirase S; Kubokawa I; Mori T; Yanai T; Hayakawa A; Takeshima Y; Nishio H; Matsuo M; Imadome K; Iijima K
Eur J Pediatr; 2014 Dec; 173(12):1615-8. PubMed ID: 24169729
[TBL] [Abstract][Full Text] [Related]
17. T Cell-Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis (HLH) Occurs in Non-Asians and Is Associated with a T Cell Activation State that Is Comparable to Primary HLH.
Shamriz O; Kumar D; Shim J; Briones M; Quarmyne MO; Chonat S; Lucas L; Edington H; White MH; Mahajan A; Park S; Chandrakasan S
J Clin Immunol; 2021 Oct; 41(7):1582-1596. PubMed ID: 34173902
[TBL] [Abstract][Full Text] [Related]
18. An 18-Year-Old Male With X-linked Lymphoproliferative Syndrome Type 1 Who Developed Primary Central Nervous System Lymphoma 6 Months After Primary Epstein-Barr Virus Infection.
Kusano N; Sakata N; Sugimoto K; Miyazawa T; Ueda S; Okano M; Imadome KI; Hoshino A; Kanegane H; Kimura M; Sato T; Okada M; Takemura T
J Pediatr Hematol Oncol; 2019 Nov; 41(8):e538-e541. PubMed ID: 30676439
[TBL] [Abstract][Full Text] [Related]
19. Treatment of rare co-occurrence of Epstein-Barr virus-driven post-transplant lymphoproliferative disorder and hemophagocytic lymphohistiocytosis after allogeneic stem cell transplantation.
Weber T; Wickenhauser C; Monecke A; Gläser C; Stadler M; Desole M; Ligeti K; Behrmann C; Müller-Tidow C; Müller LP
Transpl Infect Dis; 2014 Dec; 16(6):988-92. PubMed ID: 25179757
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
